| Symlin (pramlintide) / AstraZeneca |
NCT00229658: An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes |
|
|
| Completed | N/A | 1297 | US | pramlintide acetate, Symlin | AstraZeneca | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 05/08 | 05/08 | | |
NCT00842075: Pramlintide in Adolescents With Type 1 Diabetes |
|
|
| Completed | N/A | 10 | US | pramlintide, Symlin | University of Colorado, Denver, Amylin Pharmaceuticals, LLC. | Type 1 Diabetes | 12/09 | 12/09 | | |
NCT01434862: Pramlintide Combined With Model Predictive Control Algorithm |
|
|
| Terminated | N/A | 2 | US | Closed loop with pramlintide, Closed loop without pramlintide, Open loop with pramlintide | University of Virginia, The Paul Manning Foundation | Type 1 Diabetes Mellitus | 02/12 | 02/12 | | |
NCT01839370: Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus |
|
|
| Completed | N/A | 9 | US | Closed Loop with Pramlintide | University of Virginia, DexCom, Inc., Tandem Diabetes Care, Inc. | Diabetes Mellitus, Type 1 | 11/13 | 11/13 | | |
